Qiagen negotiated exclusive, worldwide distribution rights to Celera’s next-generation ResPlex II multiplex assay for the detection of respiratory pathogens. The new assay detects 19 different pathogens and is designed for use with the Luminex LiquiChip 100 and 200 instrument platforms, for which Qiagen is also a partner. The test has yet to be submitted for regulatory approval in the U.S. and Europe.

NewsAssay developmentDrug development (Research and development)Early-stage clinical drug developmentMedical devices and equipmentsMedicine, Diagnosis, and TherapeuticsMicrobiologyMicroorganismsResearch and developmentQiagen
Previous articleGenzyme and Isis Report Positive Phase III Data from Familial Hypercholesterolemia Trial
Next articleMerck & Co. Passes Late-Stage Onychomycosis Therapy Back to Anacor